Skip to content

Use of Mobile Teledermatology in the Care of Acne Patients

Use of Mobile Teledermatology in the Care of Acne Patients - A Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01399970
Acronym
Teleacne
Enrollment
69
Registered
2011-07-22
Start date
2011-04-30
Completion date
2013-01-31
Last updated
2014-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne

Keywords

Mobile Teledermatology, Telemedicine, Acne

Brief summary

The purpose of the present study is to determine whether a mobile teledermatology care model can achieve better clinical outcomes as compared to conventional, outpatient care for the management of severe acne treated with isotretinoin. The superiority of mobile care in comparison to conventional, outpatient care will be investigated regarding 1. effectiveness: Global evaluation Acne (GEA) score -response at week 24 2. safety: drop out rates and medication side effects 3. overall patient satisfaction with acne care and therapy 4. overall physician satisfaction with mobile acne care

Interventions

OTHERMobile Teleconsultation Arm (MTA)

In addition to a face-to-face visit at baseline, patients will conduct mobile visits at home every two weeks. The general practitioner of choice will perform examinations, such as laboratory or occasionally pregnancy tests every 4 weeks according to the treatment guidelines.

OTHEROutpatient Consultation Arm (OCA)

Patients will receive routine outpatient care at the clinic according to the treatment guidelines, and will be scheduled for outpatient visits every 4 weeks.

Sponsors

National Bank of Austria
CollaboratorOTHER_GOV
Medical University of Graz
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
12 Years to 30 Years
Healthy volunteers
No

Inclusion criteria

Female or male, aged 12 to 30 years * with facial acne * requiring systemic isotretinoin treatment (GEA-Score: 3-5) * with basic handy skills * with a signed consent form

Exclusion criteria

* Pregnancy or lactation period * Withdrawal of informed consent * Non-compliance, failure to comply with protocol requirements

Design outcomes

Primary

MeasureTime frameDescription
Global evaluation Acne score (GEA)week 24Change from Baseline in the median GEA score at week 24

Countries

Austria

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026